Literature DB >> 1773873

Follicular fluid steroid and epidermal growth factor content, and in vitro estrogen release by granulosa-luteal cells from patients with polycystic ovaries in an IVF/ET program.

A Volpe1, G Coukos, G D'Ambrogio, P G Artini, A R Genazzani.   

Abstract

The follicular fluid (FF) content of androgens, estrogens and epidermal growth factor (EGF) has been evaluated in a group of patients with policystic ovary disease (PCO) and in one of normally-ovulating infertile women (NOW) in an IVF/ET program. The in vitro response to follicle-stimulating hormone (FSH) has been also evaluated in granulosa luteal cells from the same patients. PCO patients showed significantly higher FF androstenedione (delta 4) and testosterone (T) and similar FF estrone (E1) and 17 beta-estradiol (E2) levels compared to controls. In vitro production of E1 and E2 by granulosa luteal cells from PCO patients and from controls were overlapping and their response to FSH was similar. These data indicate a normal intrinsic potential aromatase activity in ovaries from PCO patients stimulated with gonadotropins and suggest that PCOs do not derive from inherent ovarian aromatase deficiency. Increased FF androgen content following gonadotropin stimulation may result from theca cell hyperactivity and androgen accumulation in the follicular antrum of rescued hyperandrogenic follicles as well as from inhibitory factors that may inhibit aromatase activation in vivo, partially counteracting the effect of gonadotropins. FF EGF levels were significantly higher in the group of PCO patients compared to those of NOW. EGF may play a role in blunting the in vivo response of granulosa cells to gonadotropins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1773873     DOI: 10.1016/0028-2243(91)90219-b

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  7 in total

Review 1.  Clinical utility of adjuvant growth hormone in the treatment of patients with polycystic ovaries undergoing in vitro fertilization.

Authors:  P G Artini; A A de Micheroux; F Taponeco; V Cela; G D'Ambrogio; A R Genazzani
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

Review 2.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

Review 3.  Polysystic ovary syndrome--loss of the apoptotic mechanism in the ovarian follicles?

Authors:  R Homburg; A Amsterdam
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 4.  Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence.

Authors:  Jie Qiao; Huai L Feng
Journal:  Hum Reprod Update       Date:  2010-07-16       Impact factor: 15.610

Review 5.  Estradiol Signaling at the Heart of Folliculogenesis: Its Potential Deregulation in Human Ovarian Pathologies.

Authors:  Stéphanie Chauvin; Joëlle Cohen-Tannoudji; Céline J Guigon
Journal:  Int J Mol Sci       Date:  2022-01-03       Impact factor: 5.923

6.  PCOS women show significantly higher homocysteine level, independent to glucose and E2 level.

Authors:  Zahra Eskandari; Rajab-Ali Sadrkhanlou; Vahid Nejati; Gholamreza Tizro
Journal:  Int J Reprod Biomed (Yazd)       Date:  2016-08

7.  Follicular hyperandrogenism and insulin resistance in polycystic ovary syndrome patients with normal circulating testosterone levels.

Authors:  Andi Li; Lu Zhang; Jiajia Jiang; Nan Yang; Ying Liu; Lingbo Cai; Yugui Cui; Feiyang Diao; Xiao Han; Jiayin Liu; Yujie Sun
Journal:  J Biomed Res       Date:  2017-11-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.